Parkin disease and the Lewy body conundrum. by Doherty, KM & Hardy, J
Parkin Disease and the Lewy Body Conundrum
Karen M. Doherty, MRCP,* and John Hardy, PhD
Reta Lila Weston Institute of Neurological Studies and Research Laboratories, Departments of Molecular Neuroscience and Clinical Neuro-
science, University College London Institute of Neurology, London, United Kingdom
A clear pathologic hallmark like that identified in
sporadic Parkinson’s disease (PD) is lacking in many
of the monogenic causes of PD. In leucine-rich repeat
kinase 2 (LRRK2) mutations (PARK8), alpha-synu-
clein pathology in the form of Lewy bodies (LBs) is
frequently, but not consistently, observed. Other path-
ologies reported in LRRK2 cases include tau inclu-
sions of the Alzheimer, progressive supranuclear palsy,
and frontotemporal lobar degeneration types, and
TAR DNA-binding protein 43 (TDP-43) inclusions.1
There has been only a single report of a compound
heterozygous, phosphatase and tensin homolog
(PTEN)-induced, putative kinase 1 (PINK1; PARK6)
patient coming to autopsy.2 That patient presented
with asymmetrical rigidity at age 31 years and had a
good motor response to dopaminergic therapy, but
died at age 39 years. Pathologic study revealed nigral
neuronal loss and gliosis, with a few LBs and Lewy
neurites identified in the substantia nigra (SN), nucleus
basalis of Meynert (NBM), and reticular formation of
the brainstem, but not in the locus coeruleus (LC),
amygdala, or hippocampus. This finding is interesting,
because PINK1 and parkin share a similar clinical
phenotype, are believed to share a mechanistic path-
way in the pathogenesis of PD,3 and, overwhelmingly,
parkin-linked disease (PARK2) has been considered a
non-LB disorder.
Case reports of genetically confirmed parkin disease
and our recent case series of 5 unrelated parkin com-
pound heterozygotes describe the pathology of parkin
disease as a severe nigropathy with LBs present in
only a minority of patients.4–15 The LC is consistently
affected by neuronal loss, and tau pathology is occa-
sionally described but is not a significant feature.
Miyakawa and colleagues describe the first homozy-
gous parkin disease case with definite LB pathology at
postmortem examination.16 The female patient devel-
oped gait difficulty at age 61 years, and examination
revealed all the cardinal features of PD. She appeared
to respond well to dopaminergic therapy and devel-
oped motor fluctuations after 7 years, which were
managed with bilateral deep-brain stimulation of the
subthalamic nuclei. Her parents were first cousins, and
her mother also possibly was affected. She was homo-
zygous for deletions of exons 2 through 4 of parkin.
Neuropathologic examination after 11 years of disease
revealed a depigmented SN and LC. Histopathologic
study confirmed SN neuronal loss with LBs and Lewy
neurites in various brainstem nuclei (SN, LC, dorsal
motor nucleus of the vagus, and NBM), the amygda-
loid nucleus, the striatum, and the anterior cingulate
cortex without evidence of other significant patholo-
gies. Those authors suggested that the presence of
truncated parkin protein (assumed to result from the
homozygous deletion) may have resulted in LB forma-
tion; and they also considered the older age of onset
but eventually concluded that coexistent sporadic PD
may have led to the pathologic changes described.
There are several possible theories regarding the
finding of LB pathology in both parkin and PINK1-
related disease. First, it is possible that the LBs identi-
fied in these patents represent incidental LB disease
(iLBD), which is described on postmortem examina-
tion in controls of increasing age,17–19 ie, the LBs rep-
resent presymptomatic PD, but the parkin or PINK1
mutations have produced the clinical syndrome. The
patient reported by Miyakawa et al., although
aged>70 years at death, had Braak stage IV20 LB pa-
thology, which extends beyond what is considered
iLBD. That brings us to the authors’ conclusion that
their case had coincidental sporadic PD. The patient’s
age at onset (61 years) was typical for sporadic PD,
and it is possible the parkin phenotype had not yet
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become clinically established; we note that there exist
occasional reports of parkin cases that did not mani-
fest any signs of parkinsonism at ages well above that
expected (>55 years),8,21 but those cases were com-
pound heterozygous, and the possibility of reduced
penetrance of 1 mutant allele would not apply in the
homozygous situation. Conversely, the family history
suggests that PD was not sporadic: the patient’s
parents were first cousins, and her mother possibly
also suffered from parkinsonism. Like the cases
reported by Farrer et al.8 and Pramstaller et al.,12 this
produces an atypical inheritance pattern for parkin
disease and makes us wonder about digenic disease
and whether other genes, such as LRRK2, had been
considered.
Age at disease onset is an intriguing explanation for
the finding of LBs at postmortem examination in
patients with parkin disease and is supported by the
fact that no juvenile-onset cases have ever been
reported with LBs postmortem.22,23 We have analyzed
the age of onset in all reported cases and observed that
the patients with LBs were significantly older when
their symptoms began (mean age of onset: without LBs
postmortem, 27 years; with LBs postmortem, 46
years).15 We can speculate that patients with a younger
age at onset may have a different mechanism for deal-
ing with abnormal protein accumulation; as a result,
only neuronal dropout and gliosis are the neuropatho-
logic findings when the disease overwhelms.
Before this case and that reported by Sasaki et al.11
it was assumed that large homozygous deletions of
parkin were not associated with a-synuclein pathology
because of the complete loss of parkin protein func-
tion, whereas incomplete loss of function is recognized
with some missense mutations.24 The argument of
partial protein function resulting from compound het-
erozygous mutations may explain the LBs found post-
mortem in the young onset PINK1 case2 but holds less
well for this recent parkin case, in which homozygous
deletions of exons 2 through 4 are likely to have ren-
dered the resulting protein completely lacking in
function.
Another interesting point is the patient’s cardiac io-
dine-131 metaiodobenzylguanidine (MIBG) imaging.
Decreased uptake of MIBG indicates cardiac sympa-
thetic denervation and is typical for sporadic PD. The
imaging was normal in this patient, as has been
reported before in parkin-linked disease,14,25 in which
it was suggested to signify the absence of LB pathol-
ogy in parkinsonism cases.14 The relative preservation
of epicardial sympathetic fascicles observed postmor-
tem was in keeping with the antemortem imaging, but
a-synuclein aggregates and LBs also were discovered
in these structures.
The consistent neuropathologic findings in parkin
disease remain those of severe SN and moderate LC
neuronal loss. The variable findings of LBs and tau
inclusions are not pathognomic or imperative for the
condition. The discrepancy between areas of neuronal
loss and areas of LB pathology described in the car-
diac sympathetic system in this case provides addi-
tional support that these processes are not closely
linked in parkin disease. The selective localization of
the lesion in parkin disease is reminiscent of the local-
ization of the lesion in 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (MPTP)-induced parkinsonism.26
Parkin is a protein with the function of mitochondrial
quality control,3 and MPTP is a mitochondrial
toxin.27 The extent to which the nigral selectivity in
MPTP-related disease reflects this mitochondrial
selectivity or reflects selective uptake of the MPTP
metabolite 1-methyl-4-phenylpyridinium (MPP1) into
dopaminergic neurons28 is deserving of further study.
In summary, the clinical features and corresponding
pathologic lesion of parkin disease appear to be dis-
tinct from those of sporadic PD, but the correlation
remains unclear between the clinical syndrome of par-
kinsonism, the pathologic finding of LBs, and the
underlying genetic predispositions of these features in
the context of variable ages of onset.
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